Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) has reported its financial results for the fourth quarter and full year ended December 31, 2025. The company achieved record quarterly and full-year total Sublocade® net revenue of $252 million and $856 million, respectively. Quarterly and full-year GAAP net income reached $102 million and $210 million, while non-GAAP net income hit $107 million and $320 million.
The company's total net revenue for the quarter ended December 31, 2025, was $358 million, marking a 20% increase year-over-year. Total Sublocade net revenue for the same period was $252 million, up 30% year-over-year. Additionally, adjusted EBITDA for the quarter was $142 million, representing a significant 91% increase year-over-year.
For the full year ended December 31, 2025, total net revenue totaled $1,239 million, a 4% increase year-over-year. Meanwhile, total Sublocade net revenue reached $856 million, reflecting a substantial 13% increase year-over-year. The company’s GAAP net income for the full year was $210 million, compared to $7 million for the previous year, while non-GAAP net income was $320 million, up from $240 million in the prior year, representing a 33% increase.
Indivior's business highlights for the year include growing total Sublocade full-year 2025 net revenue to $856 million, up 13% year-over-year, and launching a nationwide direct-to-consumer campaign to expand awareness of Sublocade and long-acting injectables for the treatment of opioid use disorder. Additionally, the company concluded the legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million associated with the matter.
Moreover, the company successfully completed the redomiciliation from the United Kingdom to the United States on January 26, 2026. Indivior also announced a new share repurchase program of up to $400 million.
Looking ahead, Indivior reaffirmed its full-year 2026 financial guidance, which includes net revenue in the range of $1,125 million to $1,195 million, total Sublocade net revenue of $905 million to $945 million, non-GAAP operating expenses of $430 million to $450 million, and adjusted EBITDA in the range of $535 million to $575 million.
The company’s strong financial performance and strategic initiatives indicate a positive outlook for Indivior as it continues to focus on accelerating growth and creating value for its shareholders. Following these announcements, the company's shares moved -1.05%, and are now trading at a price of $32.54. If you want to know more, read the company's complete 8-K report here.
